Plasma renin levels were determined in the academia-driven, EU-funded “Labeling of Enalapril from Neonates up to Adolescents” (LENA) project to evaluate its role in pediatric heart failure. Quality-controlled bioanalysis is crucial to ensure reliable data generation. However, a comprehensive bioanalytical quality control (QC) concept to monitor the method performance within an academic environment was lacking.
Thus, a QC concept was designed encompassing regulatory guidance, international recommendations and current scientific discussions. The concept included (1) a system-suitability test, (2) verification of single bioanalytical runs by calibration curve performance and evaluation of QCs, (3) assessment of the inter-run accuracy according to Clinical Laboratory Standards Institute (CLSI) guideline, (4) monitoring of reproducibility by pediatric incurred samples, (5) blank-sample analysis and (6) participation in interlaboratory testing.
The concept was successfully applied to the academic project. About 11% of single runs were identified as invalid and triggered a re-analysis of unknown samples being included in those runs. The usefulness of the customized inter-run monitoring was demonstrated and proved the good accuracy from the first to the last run. All 147 reanalyzed incurred sample pairs complied with regulatory requirements.
The regulatory complied QC concept was customized for the demands of academia-driven pediatric trials and contributed to the reliable quantification of 965 pediatric renin samples.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement n°602295 (LENA), Funder Id: http://dx.doi.org/10.13039/100011272.
Employment or leadership: The authors M. Feickert, I. Burdman, N. Makowski and M. Ali were financially supported by the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 602295 (LENA). The author B.B. Burckhardt was head of bioanalysis within the LENA project.
Honorarium: None declared
Competing interests: The funding organization played no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
1. Schroten NF, Gaillard CA, Van Veldhuisen DJ, Szymanski MK, Hillege HL, De Boer RA. New roles for renin and prorenin in heart failure and cardiorenal crosstalk. Heart Fail Rev 2012;17:191–201.10.1007/s10741-011-9262-2Search in Google Scholar PubMed PubMed Central
2. Buchhorn R, Hulpke-wette M, Ruschewski W, Ross RD, Fielitz J, Pregla R, et al. Function and cardiac remodelling in congenital cardiac disease. Cardiol Young 2003;13:36–43.10.1017/S1047951103000076Search in Google Scholar
3. Buchhorn R, Hammersen A, Bartmus D, Bürsch J. The pathogenesis of heart failure in infants with congenital heart disease. Cardiol Young 2001;11:498–504.10.1017/S1047951101000725Search in Google Scholar
4. Jacobs JP, Quintessenza JA, Karl TR, Asante-Korang A, Everett AD, Collins SB, et al. Summary of the 2015 international paediatric heart failure summit of Johns Hopkins All Children’s Heart Institute. Cardiol Young 2015;25(S2):8–30.10.1017/S1047951115001353Search in Google Scholar PubMed
6. Stout KK, Broberg CS, Book WM, Cecchin F, Chen JM, Dimopoulos K, et al. Chronic Heart Failure in Congenital Heart Disease: a scientific statement from the American Heart Association. Circulation 2016;133:770–801.10.1161/CIR.0000000000000352Search in Google Scholar PubMed
7. Samiee-Zafarghandy S, Mazer-Amirshahi M, Van Den Anker JN. Trends in paediatric clinical pharmacology data in US pharmaceutical labelling. Arch Dis Child 2014;99:862–5.10.1136/archdischild-2013-305605Search in Google Scholar PubMed
8. Bajcetic M, de Wildt SN, Dalinghaus M, Breitkreutz J, Klingmann I, Lagler FB, et al. Orodispersible minitablets of enalapril for use in children with heart failure (LENA): rationale and protocol for a multicentre pharmacokinetic bridging study and follow-up safety study. Contemp Clin Trials Commun 2019;15:100393.10.1016/j.conctc.2019.100393Search in Google Scholar PubMed PubMed Central
9. Campbell DJ, Nussberger J, Stowasser M, Danser AH, Morganti A, Frandsen E, et al. Activity assays and immunoassays for plasma renin and prorenin: information provided and precautions necessary for accurate measurement. Clin Chem 2009;55:867–77.10.1373/clinchem.2008.118000Search in Google Scholar PubMed
10. Food and Drug Admistration (FDA). Guidance for industry: bioanalytical method validation. U.S. Department of Health and Human Services. May 2018.Search in Google Scholar
11. Martin GP, Barnett KL, Burgess C, Curry PD, Ermer J, Gratzl GS, et al. Stimuli to the revision process: proposed new USP general chapter: the analytical procedure lifecycle <1220>. Pharmacopeial Forum 2017;1:1 9.Search in Google Scholar
12. International Council for Harmonization (ICH). Q14: analytical procedure development and revision of Q2(R1) analytical validation. Vol. 2. 2018:2018–20.Search in Google Scholar
13. Martin GP, Barnett KL, Burgess C, Curry PD, Ermer J, Gratzl GS, et al. Lifecycle management of analytical procedures: method development, procedure performance qualification, and procedure performance verification. Pharmacopeial Forum 2013;39:1–16.Search in Google Scholar
15. De Plato F, Fontana C, Gherardi G, Privitera GP, Puro V, Rigoli R, et al. Collection, transport and storage procedures for blood culture specimens in adult patients: recommendations from a board of Italian experts. Clin Chem Lab Med 2019;57:1680–9.10.1515/cclm-2018-1146Search in Google Scholar PubMed
17. Schaefer J, Burckhardt BB, Tins J, Bartel A, Laeer S. Validated low-volume immunoassay for the reliable determination of direct renin especially valuable for pediatric investigations. J Immunoass Immunochem 2017;38:579–94.10.1080/15321819.2017.1350707Search in Google Scholar PubMed
18. International Council for Harmonization (ICH). ICH guideline M10 on bioanalytical method validation. Vol. 44, EMEA Guidance Document. 2019.Search in Google Scholar
19. Broadhurst D, Goodacre R, Reinke SN, Kuligowski J, Wilson ID, Lewis MR, et al. Guidelines and considerations for the use of system suitability and quality control samples in mass spectrometry assays applied in untargeted clinical metabolomic studies. Metabolomics 2018;14:1–17.10.1007/s11306-018-1367-3Search in Google Scholar PubMed PubMed Central
20. Azadeh M, Sondag P, Wang Y, Raines M, Sailstad J. Quality controls in ligand binding assays: recommendations and best practices for preparation, qualification, maintenance of lot to lot consistency, and prevention of assay drift. AAPS J 2019;21:89.10.1208/s12248-019-0354-6Search in Google Scholar PubMed PubMed Central
21. Danilenko U, Vesper HW, Myers GL, Clapshaw PA, Camara JE, Miller WG. An updated protocol based on CLSI document C37 for preparation of off-the-clot serum from individual units for use alone or to prepare commutable pooled serum reference materials. Clin Chem Lab Med 2020;58:368–74.10.1515/cclm-2019-0732Search in Google Scholar PubMed PubMed Central
22. Parvin CA, Person NB, Baumann N, Duan L, Durham AP, Genta VM, et al. What’s new in statistical quality control guidance: CLSI’s C24 updates CLSI C24 – 4th ed. Statistical quality control for quantitative measurement procedures: principles and definitions, 2016:1–21.Search in Google Scholar
23. Bruijnsvoort MV, Meijer J, Den Beld CV. The application of control charts in regulated bioanalysis for monitoring long-term reproducibility. Bioanalysis 2017;9:1955–65.10.4155/bio-2017-0163Search in Google Scholar PubMed
25. Ali M, Tins J, Burckhardt BB. Fit-for-purpose quality control system in continuous bioanalysis during long-term pediatric studies. AAPS J 2019;21:104.10.1208/s12248-019-0375-1Search in Google Scholar PubMed
©2020 Walter de Gruyter GmbH, Berlin/Boston